Showing 4511-4520 of 8895 results for "".
- Research: Slow-release Nitric Oxide Particles May Reduce Inflammatory Acnehttps://practicaldermatology.com/news/research-slow-release-nitric-oxide-particles-may-reduce-inflammatory-acne/2458910/GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology. This research, published in the Journal of Investigative Dermatology, identified that the nanoparticles were eff
- Heliocare Earns NSF Good Manufacturing Practice Registration For IFC Manufacturing Facilityhttps://practicaldermatology.com/news/heliocare-earns-nsf-good-manufacturing-practice-registration-for-ifc-manufacturing-facility/2458911/Ferndale Healthcare, Inc.’s IFC manufacturing facility for its Heliocare® brand is now a Good Manufacturing Practices (GMP) facility registered by NSF International, an independent organization recognized as the world leader in standards development, product certification, ed
- DermatologistOnCall Launches New Mobile Apphttps://practicaldermatology.com/news/dermatologistoncall-launches-new-mobile-app/2458919/DermatologistOnCall launched a new mobile app that it says enables patients to quickly and easily start and complete an online visit with a board-certified dermatologist. The app is free and works with Apple's iPhones and iPads, and Android phones and tablets. "Our new mobile app
- David Dobrowski Named Vice President, Head of North American Research and Development at Merzhttps://practicaldermatology.com/news/david-dobrowski-named-vice-president-head-of-north-american-research-and-development-at-merz/2458921/Merz North American appointed David Dobrowski Vice President and Head of North American Research and Development, effective immediately. In this role, Mr. Dobrowski is responsible for all medical, regulatory, and product safety functions for Merz in North America. He leads the planning and execut
- National Psoriasis Foundation Awards Half a Million Dollars in Fellowshipshttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-half-a-million-dollars-in-fellowships/2458922/Eleven early-career physicians each received a one-year, $50,000 National Psoriasis Foundation Medical Dermatology Fellowship to study psoriasis and psoriatic arthritis. These fellowships will help increase the number of scientists studying
- Neutrogena Sunscreens Awarded NEA Seal of Acceptancehttps://practicaldermatology.com/news/neutrogena-sunscreens-awarded-nea-seal-of-acceptance/2458928/The National Eczema Association (NEA) awarded its Seal of Acceptance to five Neutrogena sunscreens. This recognition is given to product innovations that help improve the quality of life for people with eczema, empowering consumers to make informed eczema purchase decisions. The fol
- NIH Funding Often Does Not Match Disease Burden for Dermatologic Conditionshttps://practicaldermatology.com/news/nih-funding-often-does-not-match-disease-burden-for-dermatologic-conditions/2458930/A new analysis of funding prioritization by the National Institutes of Health for skin disease offers a glimpse of cutaneous skin disease on a national level, with some disease states being possibly underfunded. Examining the relationship between dermatologic research funding and skin disease bur
- Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio With Topical Nano-Formulated Cyclosporine Ahttps://practicaldermatology.com/news/immune-pharmaceuticals-expands-immuno-dermatology-development-portfolio-with-topical-nano-formulated-cyclosporine-a/2458932/Immune Pharmaceuticals Inc. entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem regarding the worldwide exclusive licensing and development of a topical, biodegradable, nano-capsule formulation of cyclospo
- InMed Pharmaceuticals Files Provisional Patent for Novel Compounds to Treat Epidermolysis Bullosa Simplexhttps://practicaldermatology.com/news/inmed-pharmaceuticals-files-provisional-patent-for-novel-compounds-to-treat-epidermolysis-bullosa-simplex/2458939/InMed Pharmaceuticals Inc. filed a provisional patent application with the United States Patent and Trademark Office relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed. Dr. Sazzad Hossain, InMed Pha
- The American Academy of Dermatology Elects New Officers and Board Membershttps://practicaldermatology.com/news/the-american-academy-of-dermatology-elects-new-officers-and-board-members/2458941/The American Academy of Dermatology (AAD) announced the results of its annual election. The newly elected officers and board members will lead the AAD, which represents more than 19,000 physicians. These officers and board members also will hold the same positions for the American Academy of Derm